AI in Pharma: Transforming Quality, Manufacturing, and Workforce Readiness
Why This ISPE Podcast Episode Is a Must Listen for Industry Innovators
Artificial intelligence (AI) continues to redefine how pharmaceutical companies develop products, ensure quality, and manage complex global operations.
In a recent episode of ISPE Podcast: Shaping the Future of Pharma, ISPE’s official podcast, host Bob Chew leads an in-depth discussion with several industry leaders at the forefront of AI adoption:
- Magaly Aham, Senior Vice President, Head of Global Quality Compliance and Systems, Takeda
- Eric Staib, Vice President, Corporate Quality, Syneos Health
- Benjamin Stevens, Senior Director of Chemistry, Manufacturing, and Controls Policy and Advocacy, Alnylam Pharmaceuticals
Together in this compilation episode, they explore practical applications, regulatory perspectives, organizational readiness, and the next wave of digital transformation that is reshaping the pharmaceutical ecosystem.
Building a Community Around AI Innovation
The conversation begins with an overview of ISPE’s AI Community of Practice (CoP), a rapidly expanding group representing large pharma, biotech, contract development and manufacturing organizations, clinical research, and technology leaders. As interest in AI accelerates, this community is establishing a collaborative environment for education, best practices, and shared problem-solving.
Participants highlight that the CoP is organized into active subcommittees focused on:
- Applications and use cases
- Model and data preparedness
- Workforce development
- Regulatory considerations
These groups connect with existing ISPE structures—including GAMP® and Pharma 4.0™—to create a cohesive, forward-looking framework for responsible AI adoption.
AI’s Practical Value: From Deviation Investigations to Process Insights
One of the most compelling examples shared in the episode involves an AI assistant designed to streamline deviation investigation reporting. The system guides investigators through structured prompts covering problem statements, scope, and impact assessments. Once responses are entered, the AI generates a comprehensive narrative, improving report quality, and significantly reducing repetitive manual drafting. Multilingual capabilities in English, German, French, and Japanese illustrate how organizations are scaling digital tools across global operations.
Beyond quality documentation, companies are leveraging AI for process development and monitoring. Multivariate statistical process monitoring, for instance, uses models to predict excursions in critical process parameters or quality attributes. These tools operate alongside—not within—good manufacturing practice systems to provide early warnings and actionable insights without modifying validated process controls.
Digital Twins: Bridging Physical Operations and Data-Driven Decision Making
Digital twins are another area of rapid advancement. While not inherently AI, digital twins serve as real-time digital representations of physical processes. When connected to machine learning models, they enable powerful predictive and optimization capabilities.
Companies are implementing digital twins in both R&D and manufacturing to:
- Forecast process performance
- Identify risks earlier
- Enhance development cycles through virtual experimentation
- Support operators with contextualized, data driven decision support
These technologies are already delivering value by shifting organizations away from reactive “firefighting” toward anticipatory, data driven operations.
Preparing the Pharma Workforce for an AI-Driven Future
A recurring theme throughout the episode is the critical need to equip employees with the knowledge and confidence to use AI tools effectively. Many organizations are investing heavily in training programs, certifications, and dedicated AI labs where staff can experiment safely with new technologies.
Workforce preparedness efforts include:
- Training employees on how to prompt AI and use large language models responsibly
- Establishing governance structures to evaluate value, scalability, and risk
- Creating internal frameworks that allow innovation while maintaining compliance
This cultural shift is essential, ensuring that AI adoption enhances scientific, operational, and quality activities, instead of complicating them.
Regulators Are Engaging and Supportive
While the industry often anticipates regulatory hurdles, the experts emphasize that regulators such as the US Food and Drug Administration and European Medicines Agency have shown strong interest in engaging with companies and encouraging responsible AI innovation. Many perceived obstacles stem from uncertainty rather than explicit regulatory barriers.
As new guidance emerges—including the ISPE GAMP® Guide: Artificial Intelligence—regulators and industry are becoming more aligned on expectations, acceptable use cases, and evidence requirements. This alignment is accelerating momentum across the sector.
What’s Next for AI in Pharma?
The episode concludes with an optimistic view of AI’s trajectory. With generative AI, machine learning, and digital twins delivering demonstrable value—and with regulatory guidance evolving—AI adoption is expected to continue expanding rapidly. The focus now shifts to identifying the areas where AI truly excels, understanding limitations, and ensuring data governance structures support long term success.
Listen to the Full Conversation
This episode of ISPE Podcast: Shaping the Future of Pharma offers a clear, practical, and forward-thinking exploration of AI’s role in transforming pharmaceutical development and manufacturing. Listeners will gain valuable insights into where the technology stands today, the challenges organizations are overcoming, and how the industry is preparing for the next wave of digital innovation. To hear the full discussion and stay ahead of emerging trends, be sure to listen to the complete episode and subscribe to the ISPE podcast.
